Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of TAGRISSO (osimertinib) in NSCLC patients with T790M mutation detected by liquid biopsy
KCT0003232Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Jan 2018; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on KCT0003232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003232.